Armitage J O, Dick F R, Platz C E, Corder M P, Leimert J T
Am J Med. 1979 Dec;67(6):929-34. doi: 10.1016/0002-9343(79)90632-6.
Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p less than 0.001), and to that of those with large cleaved cells (p less than 0.05) and large cleaved and large noncleaved cells (p less than 0.025). All the patients with large noncleaved cells are alive and "off" therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.
31例Ⅲ期和Ⅳ期弥漫性组织细胞淋巴瘤（DHL）患者均接受了环磷酰胺、阿霉素、长春新碱和强的松（CHOP）联合治疗。两名血液病理学家将这些患者独立分为主要为大无裂细胞组（8例）、主要为大裂细胞组（7例）、大裂细胞与大无裂细胞混合组（11例）、具有免疫母细胞肉瘤特征的肿瘤组（2例）和未分类组（3例）。应用该分类法的符合率为85%。大无裂细胞患者作为一个整体的生存率优于其他患者组（p<0.001），也优于大裂细胞患者（p<0.05）和大裂细胞与大无裂细胞混合患者（p<0.025）。所有大无裂细胞患者均存活且停止治疗，无疾病进展迹象。这种组织学分类似乎识别出了一组晚期弥漫性组织细胞淋巴瘤患者，这些患者具有大无裂细胞，接受CHOP治疗时预后极佳。
